Tweet
Am J Clin Pathol
. 2020 Nov 6;aqaa228.
doi: 10.1093/ajcp/aqaa228. Online ahead of print.
Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening
Megan Zilla 1 , Bradley J Wheeler 2 , Christian Keetch 1 , Gretchen Mitchell 1 , Jeffrey McBreen 1 , Alan Wells 1 3 , Michael R Shurin 1 4 , Octavia Peck-Palmer 1 5 , Sarah E Wheeler 1 6
Affiliations
- PMID: 33155015
- DOI: 10.1093/ajcp/aqaa228
Abstract
Objectives: Serologic detection of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is needed for definition of convalescent plasma donors, for confounding SARS-CoV-2 presentation, and for seroprevalence studies. Reliable serologic assays with independent validation are required.
Methods: Six SARS-CoV-2 antibody assays from Beckman Coulter, Euroimmun (IgG, IgA), Roche, and Siemens (Centaur, Vista) were assessed for specificity (n = 184), sensitivity (n = 154), and seroconversion in a defined cohort with clinical correlates and molecular SARS-CoV-2 results.
Results: Assay specificity was 99% or greater for all assays except the Euroimmun IgA (95%). Sensitivity at more than 21 days from symptom onset was 84%, 95%, 72%, 98%, 67%, and 96% for Beckman Coulter, Centaur, Vista, Roche, Euroimmun IgA, and Euroimmun IgG, respectively. Average day of seroconversion was similar between assays (8-10 d), with 2 patients not producing nucleocapsid antibodies during hospitalization.
Conclusions: SARS-CoV-2 nucleocapsid antibodies may be less reliably produced early in disease than spike protein antibodies. Assessment of convalescent plasma donors at more than 30 days from symptom onset and seroprevalence studies should use assays with defined sensitivity at time points of interest because not all assays detected antibodies reliably at more than 30 days.
Keywords: Antibody; COVID-19; Coronavirus; SARS-CoV-2; Serology.